Miriam Zimmermann

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Machine Learning

Radical Prostatectomy

Ejection Fraction

Top Venues

Arthritis & rheumatology (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Pascal Richette, Marijn Vis, Sarah Ohrndorf, William Tillett, Julio Ramírez, Marlies Neuhold, Michel van Speybroeck, Elke Theander, Wim Noel, Miriam Zimmermann, May Shawi, Alexa Kollmeier, Alen Zabotti
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA. RMD open 9 (1) (2023)